AI in Medicine: Life Sciences and Drug Discovery - AI Trends

Michael Krigsman: Artificial intelligence in drug discovery is a relatively new field. Thank you so much for watching. Before we begin, please subscribe on YouTube and subscribe to our newsletter. You can do that right now. Alex Zhavoronkov, he is the CEO of Insilico. Tell us briefly about Insilico Medicine and tell us the things that you're working on. Alex Zhavoronkov: We are focused primarily on applying next-gen AI techniques to drug discovery, biomarker development, and also aging research. We focus specifically on two machine learning techniques. Those are the techniques we are most expert in our field. We use those techniques for two purposes. One is identifying biological targets and constructing biomarkers from multiple data types and also generating new molecules, new molecular structures with a specific set of properties. We were one of the first companies, possibly the first one, to generate new molecules using this new technique called generative adversarial networks–it's kind of AI imagination–and validate those molecules experimentally.